Bispecific antibodies (BsAbs) are a class of artificial proteins that are engineered to recognize two different antigens or epitopes. This capability allows them to simultaneously engage two different types of targets, such as cancer cells and immune cells, which can enhance the body's immune response against tumors or address complex diseases that require the modulation of multiple biological pathways. Bispecific antibodies represent a significant advancement in therapeutic antibody engineering and offer promising strategies for the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases.
Playback speed
×
Share post
Share post at current time
Share from 0:00
0:00
/
0:00
Transcript
Bispecific antibodies (BsAbs), Antibody Discovery and Therapeutics
Luke McLaughlin, Biotech Digital Marketer, Business Developer and Life Science Content Creator
Jul 07, 2024

BioTechRvs Biotechnology Reviews Journal
Biotechnology Reviews mission is to be a knowledge bridge, providing articles covering cutting edge research and developments beyond mere headlines. Providing both the backbone and structural knowledge at all levels of interest to Biotechnology enthusiasts, professionals, investors and scientists.
Our comprehensive journal delves deep into the most relevant research, providing you with valuable insights into emerging trends, cutting-edge innovations, and significant developments that are shaping the biotech industry.
Biotechnology Reviews mission is to be a knowledge bridge, providing articles covering cutting edge research and developments beyond mere headlines. Providing both the backbone and structural knowledge at all levels of interest to Biotechnology enthusiasts, professionals, investors and scientists.
Our comprehensive journal delves deep into the most relevant research, providing you with valuable insights into emerging trends, cutting-edge innovations, and significant developments that are shaping the biotech industry.Listen on
Substack App
Spotify
RSS Feed
Recent Episodes
Share this post